Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cytarabine
Find trials that include:  Any drugs shown
Results 1-25 of 147 for your search:
Start Over
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
Chemotherapy or Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1227, NCI-2013-01746, CIR00000621, NA_00071844 / CR00001237, NA_00071844, NCT01588951
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, COG-AAML1031, CDR0000701850, NCT01371981
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 91 days to 3 years
Trial IDs: AAML1531, NCI-2015-00324, NCT02521493
Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: AC220-A-U302, NCI-2016-00846, 2015-004856-24, NCT02668653
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB00001012, NCI-2013-00787, CR00022596, HEM-08059-LX, MR00041596, SOL-05025-L, MR00045915, SOL-05025-LM, OHSU-1012, OHSU-SOL-05025-L, NCT00293475
Clofarabine or Fludarabine Phosphate in Combination with Idarubicin and Cytarabine in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0788, NCI-2011-00251, NCT01289457
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2010-0991, NCI-2011-01123, NCT01371630
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, P11859, 120003, NCT01468311
Donor Natural Killer Cells in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 59
Trial IDs: 2012-0079, NCI-2014-00883, NCI-2014-00841, NCT01787474
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: RT12-US-AML-a, NCI-2013-01362, NCT01795924
Start Over